The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 10, 2023

Filed:

Jun. 21, 2019
Applicant:

Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);

Inventors:

Andrew J. Murphy, Croton-on-Hudson, NY (US);

Dimitris Skokos, New York, NY (US);

Janelle Waite, Bronx, NY (US);

Erica Ullman, Yorktown Heights, NY (US);

Aynur Hermann, New York, NY (US);

Eric Smith, New York, NY (US);

Lauric Haber, Rye Brook, NY (US);

George D. Yancopoulos, Yorktown Heights, NY (US);

Assignee:

Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); C07K 16/30 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2818 (2013.01); C07K 16/3069 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/565 (2013.01); C07K 2317/732 (2013.01); C07K 2317/734 (2013.01); C07K 2317/74 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01);
Abstract

The present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD28, and a second antigen-binding molecule that specifically binds human PSMA. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing PSMA, such as prostate tumors. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an up-regulated or induced targeted immune response is desired and/or therapeutically beneficial.


Find Patent Forward Citations

Loading…